Technology
Health
Pharmaceutical

Reata Pharmaceuticals

$88.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.05 (1.21%) Today
+$0.77 (0.89%) After Hours

Why Robinhood?

You can buy or sell RETA and other stocks, options, ETFs, and crypto commission-free!

About

Reata Pharmaceuticals, Inc. Class A Common Stock, also called Reata Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Read More Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

Employees
123
Headquarters
Irving, Texas
Founded
2002
Market Cap
2.63B
Price-Earnings Ratio
โ€”
Dividend Yield
0.00
Average Volume
284.85K
High Today
$89.04
Low Today
$86.32
Open Price
$86.99
Volume
51.26K
52 Week High
$104.53
52 Week Low
$32.89

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2016 IPO
US
North America

News

Seeking AlphaMay 24

Reata Bardoxolone Trial Success Likely, But Still Just A Hold

Reata Pharmaceuticals (RETA) is a late clinical stage biotechnology company with a chronic kidney disease therapy due to release results later this year.

12
Seeking AlphaMay 9

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2019 Results - Earnings Call Transcript

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q1 2019 Results Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Adam Walsh - Stifel Joseph Swartz - SVP Leerink Maury Raycroft - Jefferies Brian Skorney - Baird Operator Good day, ladies and gentlemen, and welcome to the Reata Pharmaceuticals First Quarter Financial Results and Update on Devel...

38
Yahoo FinanceMay 9

Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Reata Pharmaceuticals, Inc. (RETA) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise ...

17

Earnings

-$1.08
-$0.67
-$0.26
$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
โ€”
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.